deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT04401202

Nigella Sativa in COVID-19

Effects of Nigella Sativa as a Treatment of Patients With Upper Respiratory Tract Infection Caused by SARS-coronavirus-2: a Prospective, Randomized, Open-label, Controlled Clinical Study

Sponsor: King Abdulaziz University

Conditions COVID-19 SARS-CoV-2
Interventions Nigella sativa oil
Updated 5 times since 2020 Last updated: May 25, 2021 Started: May 21, 2020 Primary completion: Dec 31, 2020 Completion: Dec 31, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on COVID-19 and SARS-CoV-2, this trial is completed. The trial is conducted by King Abdulaziz University and has accumulated 5 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshotRecruiting~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Jul 2024 · 37 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jun 2021 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  4. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  5. Jun 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    First recorded

May 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • King Abdulaziz University
Data source: King Abdulaziz University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations